Monday , December 6 2021

Succeeding to drive one of the most deadly cancers by first burning the tumor with a needle


Doctors at Vall d'Hebron Hospital in Barcelona, ​​Spain, have successfully driven three patients suffering from advanced pancreatic cancer, the one who has the worst prognosis, and so far did not work, applied a groundbreaking technology that burns tumor cells.

It is about intraoperative radio frequency, which has been applied to counter locally advanced adenocarcinoma in the pancreas. This type of advanced cancer is considered to be the worst prognosis among pancreatic tumors, with a average survival of 11 months.

the adenocarcinoma in the pancreas Locally advanced can not be used with traditional techniques due to the involvement of major arteries and veins and are not effective treatments such as chemotherapy or immunotherapy.

However, the intraoperative radio frequency, applied in the context of an international study led by Dutch experts, allows to insert a needle directly into the tumor destroy tumor cells through heat. The three patients undergoing surgery with this new technique did not present any type of complication.

"The needle breaks the shield [tras el que se esconde el tumor] and allows us to apply temperatures up to 80ºC directly in the tumor zone. These temperatures are so high they literally burn the tumor causes cell death. This process also facilitates the exposure of tumor components for the immune cells to attack them, Dr. Elizabeth Pando in Vall d 'Hebron Hospital.

To prevent high temperatures from causing damage to organs, arteries and other important areas close to the adenocarcinoma of the pancreas, the needle also has a cooling system, which allows the introduction of coolants that reach areas like duodenum to prevent overheating.

The results of the study will be known in 2021. "If it is confirmed that this therapy is effective for locally advanced adenocarcinoma in the pancreas, we will eventually have a technology that allows improve the prognosis for this tumor so malignant, "added Dr. Ramón Charco, Head of Hepatobiliary and Transplant Surgery Service at the Spanish Hospital.

Source link